Abrdn Life Sciences Investors (HQL) Competitors $12.58 -0.14 (-1.06%) Closing price 05/21/2025 03:58 PM EasternExtended Trading$12.64 +0.05 (+0.40%) As of 05/21/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HQL vs. CET, GSBD, MFIC, NMFC, PFLT, BCSF, MUC, BBDC, AWF, and HQHShould you be buying Abrdn Life Sciences Investors stock or one of its competitors? The main competitors of Abrdn Life Sciences Investors include Central Securities (CET), Goldman Sachs BDC (GSBD), MidCap Financial Investment (MFIC), New Mountain Finance (NMFC), PennantPark Floating Rate Capital (PFLT), Bain Capital Specialty Finance (BCSF), BlackRock MuniHoldings California Quality Fund (MUC), Barings BDC (BBDC), AllianceBernstein Global High Income Fund (AWF), and Abrdn Healthcare Investors (HQH). These companies are all part of the "financial services" industry. Abrdn Life Sciences Investors vs. Central Securities Goldman Sachs BDC MidCap Financial Investment New Mountain Finance PennantPark Floating Rate Capital Bain Capital Specialty Finance BlackRock MuniHoldings California Quality Fund Barings BDC AllianceBernstein Global High Income Fund Abrdn Healthcare Investors Abrdn Life Sciences Investors (NYSE:HQL) and Central Securities (NYSE:CET) are both small-cap finance companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Which has higher earnings and valuation, HQL or CET? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbrdn Life Sciences Investors$86.69M4.19N/AN/AN/ACentral Securities$296.20M4.54N/AN/AN/A Does the media refer more to HQL or CET? In the previous week, Abrdn Life Sciences Investors had 4 more articles in the media than Central Securities. MarketBeat recorded 5 mentions for Abrdn Life Sciences Investors and 1 mentions for Central Securities. Central Securities' average media sentiment score of 1.89 beat Abrdn Life Sciences Investors' score of -0.09 indicating that Central Securities is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abrdn Life Sciences Investors 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Central Securities 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is HQL or CET more profitable? Company Net Margins Return on Equity Return on Assets Abrdn Life Sciences InvestorsN/A N/A N/A Central Securities N/A N/A N/A Is HQL or CET a better dividend stock? Abrdn Life Sciences Investors pays an annual dividend of $1.47 per share and has a dividend yield of 11.7%. Central Securities pays an annual dividend of $2.25 per share and has a dividend yield of 4.8%. Does the MarketBeat Community favor HQL or CET? Abrdn Life Sciences Investors received 95 more outperform votes than Central Securities when rated by MarketBeat users. CompanyUnderperformOutperformAbrdn Life Sciences InvestorsOutperform Votes9568.35% Underperform Votes4431.65% Central SecuritiesN/AN/A Which has more risk and volatility, HQL or CET? Abrdn Life Sciences Investors has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Central Securities has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Do institutionals and insiders hold more shares of HQL or CET? 32.2% of Abrdn Life Sciences Investors shares are held by institutional investors. Comparatively, 8.7% of Central Securities shares are held by institutional investors. 10.1% of Abrdn Life Sciences Investors shares are held by company insiders. Comparatively, 9.5% of Central Securities shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryAbrdn Life Sciences Investors beats Central Securities on 5 of the 9 factors compared between the two stocks. Get Abrdn Life Sciences Investors News Delivered to You Automatically Sign up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HQL vs. The Competition Export to ExcelMetricAbrdn Life Sciences InvestorsInvestment offices IndustryFinance SectorNYSE ExchangeMarket Cap$363.35M$6.91B$11.50B$19.42BDividend Yield16.03%6.78%5.45%3.83%P/E RatioN/A3.5722.4834.23Price / Sales4.1921.8427.2934.85Price / CashN/A7.5117.6217.51Price / BookN/A0.892.794.69Net IncomeN/A$66.51M$1.04B$1.02B7 Day Performance3.84%-0.75%-0.02%-1.74%1 Month Performance4.83%3.82%6.70%7.46%1 Year Performance-7.46%0.33%537.71%3.96% Abrdn Life Sciences Investors Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HQLAbrdn Life Sciences InvestorsN/A$12.59-1.1%N/A-10.4%$363.35M$86.69M0.00N/ADividend AnnouncementInsider TradeCETCentral SecuritiesN/A$46.75-0.5%N/A+7.8%$1.35B$296.20M0.006GSBDGoldman Sachs BDC1.5101 of 5 stars$11.33+0.4%$12.00+5.9%-27.8%$1.33B$67.93M16.19N/APositive NewsMFICMidCap Financial Investment2.6148 of 5 stars$12.87+0.1%$14.00+8.8%-19.9%$1.20B$110.35M8.25N/ANMFCNew Mountain Finance2.2006 of 5 stars$10.84+0.8%$10.67-1.6%-15.7%$1.17B$118.17M10.32N/APositive NewsPFLTPennantPark Floating Rate Capital3.4874 of 5 stars$10.34+1.1%$11.08+7.2%-11.1%$1.03B$114.06M7.39658BCSFBain Capital Specialty Finance2.0198 of 5 stars$15.76+0.5%$16.50+4.7%-5.4%$1.02B$131.73M7.921,000MUCBlackRock MuniHoldings California Quality FundN/A$10.45-0.4%N/A-5.1%$1.00B$6.39M0.00147,000News CoveragePositive NewsBBDCBarings BDC2.3375 of 5 stars$9.14+0.4%$9.33+2.1%-8.6%$963.44M$111.33M8.7926News CoverageAnalyst ForecastInsider TradeAWFAllianceBernstein Global High Income FundN/A$10.80flatN/A-1.4%$931.28M$152.17M0.00N/APositive NewsUpcoming EarningsHQHAbrdn Healthcare InvestorsN/A$15.84+1.1%N/A-7.5%$853.17M$186.46M0.00147,000News CoveragePositive NewsDividend Increase Related Companies and Tools Related Companies CET Competitors GSBD Competitors MFIC Competitors NMFC Competitors PFLT Competitors BCSF Competitors MUC Competitors BBDC Competitors AWF Competitors HQH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:HQL) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abrdn Life Sciences Investors Please log in to your account or sign up in order to add this asset to your watchlist. Share Abrdn Life Sciences Investors With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
